search

Active clinical trials for "Thrombocythemia, Essential"

Results 61-70 of 174

Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib

Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis

A lead-in cohort of ~20 patients with primary or secondary myelofibrosis previously treated with 1 or more Janus kinase inhibitors enrolled to single-agent glasdegib to evaluate safety and tolerability. Following the lead-in, a phase 2, double blind, 2-arm study, randomized 2:1 to oral single-agent glasdegib versus placebo in 201 patients resistant or intolerant to ruxolitinib.

Terminated36 enrollment criteria

A Safety Study of XL019 in Adults With Myelofibrosis

Myeloproliferative DisordersMyelofibrosis3 more

The purpose of this study is to evaluate the safety and tolerability of XL019 in adults with myelofibrosis. XL019 is a selective inhibitor of the cytoplasmic tyrosine kinase JAK2. JAK2 is activated by cytokine and growth factor receptors and phosphorylates members of the STAT family of inducible transcription factors. Activation of the JAK/STAT pathway promotes cell growth and survival, and is a common feature of human tumors. JAK2 is activated by mutation in the majority of patients with myelofibrosis, polycythemia vera and essential thrombocytosis and appears to drive the inappropriate growth of blood cells in these conditions.

Terminated13 enrollment criteria

Pacritinib Versus Best Available Therapy to Treat Myelofibrosis

Primary MyelofibrosisPost-polycythemia Vera Myelofibrosis1 more

Phase 3, randomized, controlled study to evaluate the safety and efficacy of oral pacritinib compared to Best Available Therapy (BAT) in patients with primary or secondary myelofibrosis.

Terminated15 enrollment criteria

The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line...

Essential Thrombocythemia

Prospective national multicenter randomized open label phase IIb RUXBETA trial.

Terminated44 enrollment criteria

Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia...

Primary MyelofibrosisPost-polycythemia Vera Myelofibrosis1 more

Phase 3, randomized, controlled study to evaluate the safety and efficacy of oral pacritinib compared to Best Available Therapy (BAT) in patients with thrombocytopenia and primary or secondary myelofibrosis.

Terminated19 enrollment criteria

Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib

Primary Myelofibrosis (PMF)Post-Polycythemia Vera Myelofibrosis (Post-PV MF)1 more

This is a multicenter, Phase 1b study with dose escalation and expansion cohorts designed to assess the safety, tolerability, PK, and preliminary efficacy of PU-H71 in subjects with PMF, Post-PV MF, Post-ET MF, taking stable doses of ruxolitinib.

Terminated44 enrollment criteria

Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis

MyelofibrosisPrimary Myelofibrosis2 more

This is a multicenter 2-part, Phase 1b study designed to assess the safety, tolerability, pharmacokinetics (PK) and preliminary efficacy of PU-H71 in subjects taking concomitant ruxolitinib. The first part (Dose Escalation) will employ a standard 3+3 dose escalation design to determine Maximum Tolerated Dose (MTD). The second part of the study (Dose Confirmation) will confirm the recommended Phase 2 dose (RP2D) in an expanded population.

Terminated25 enrollment criteria

Ruxolitinib Prior to Transplant in Patients With Myelofibrosis

Primary MyelofibrosisPost Polycythemia Vera Myelofibrosis1 more

The purpose of this study is to find out if giving the study drug Ruxolitinib (INC424) prior to a combination of other chemotherapeutic drugs (Fludarabine and Busulfan) before infusing another person's hematopoietic stem cells (bone marrow transplantation) will be successful in people who have advanced primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET-MF), collectively known as myelofibrosis (MF). MF is a disorder in which bone marrow tissue develops in abnormal sites because the bone marrow itself undergoes fibrosis or scarring. This study plans to evaluate whether adding the drug Ruxolitinib will further aid in reducing pre-transplant spleen size, improve physical performance levels and reduce adverse events (side effects) related to the transplant. Ruxolitinib is a drug that is approved by the FDA for the treatment of patients with advanced forms of myelofibrosis. Using Ruxolitinib prior to stem cell transplantation is experimental.

Terminated34 enrollment criteria

Anti-TGF-beta Therapy in Patients With Myelofibrosis

MyelofibrosisPrimary Myelofibrosis3 more

TGF-β is a cytokine that is found to be upregulated in the bone marrow of patients with myelofibrosis. This cytokine likely plays a dual role in promoting myelofibrosis and myeloproliferation, both of which are the bone marrow morphologic hallmark of MF. The investigators propose that inhibiting the TGF-β signaling pathway in MF will decrease the fibrogenic stimuli leading to myelofibrosis and concomitantly interrupt myeloproliferation. This is a novel approach to the treatment of patients with myelofibrosis.

Terminated28 enrollment criteria

Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients.

Primary MyelofibrosisPost-Polycythemia Vera-Myelofibrosis1 more

This was a study of treatment with ruxolitinib in patients who presented with transfusion dependent or independent anemia. Starting dose was 10 mg BID. This dose was maintained for the first 12 weeks of the study and up-titrated thereafter unless the subject met criteria for dose hold or dose reduction

Completed38 enrollment criteria
1...678...18

Need Help? Contact our team!


We'll reach out to this number within 24 hrs